Trafalgar International (GCAN) Cash from Operations Growth (3y) (2020 - 2026)
Trafalgar International (GCAN) Cash from Operations Growth (3y) (2020 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Ops. Growth (3y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 43.83 Bn | 42.86 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 42.87 Bn | 39.22 Bn | 2.15 Bn | 8.25% |
| 3 | Zoetis | 31.41 Bn | 29.73 Bn | 1.05 Bn | 52.97% |
| 4 | Takeda Pharmaceutical | 28.55 Bn | 22.75 Bn | 5.10 Bn | 5.90% |
| 5 | United Therapeutics | 22.08 Bn | 19.42 Bn | 683.80 Mn | 43.42% |
| 6 | Viatris | 18.73 Bn | 17.84 Bn | 1.46 Bn | -10.08% |
| 7 | Neurocrine Biosciences | 15.44 Bn | 15.05 Bn | 935.80 Mn | -8.76% |
| 8 | Elanco Animal Health | 11.75 Bn | 11.22 Bn | 798.00 Mn | 65.60% |
| 9 | Dr Reddys Laboratories | 10.11 Bn | 9.94 Bn | - | - |
| 10 | Trafalgar International | 236,233.75 | 236,233.75 | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 38.13% |
| Dec 31, 2025 | -8.19% |
| Sep 30, 2025 | 37.65% |
| Jun 30, 2025 | 29.81% |
| Mar 31, 2025 | -3.95% |
| Dec 31, 2024 | 60.35% |
| Sep 30, 2024 | 37.13% |
| Jun 30, 2024 | -9.05% |
| Mar 31, 2024 | 6.71% |
| Dec 31, 2023 | -4.14% |
| Sep 30, 2023 | 6.17% |
| Jun 30, 2023 | 48.65% |
| Mar 31, 2023 | 47.95% |
| Dec 31, 2022 | 3.46% |
| Sep 30, 2022 | 14.36% |
| Jun 30, 2022 | 12.40% |
| Mar 31, 2022 | 59.08% |
| Dec 31, 2021 | -41.46% |
| Sep 30, 2021 | 25.15% |
| Jun 30, 2021 | -54.58% |